These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24986083)

  • 1. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data.
    Carroll CA; Fairman KA; Lage MJ
    BMC Health Serv Res; 2014 Jul; 14():286. PubMed ID: 24986083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
    Lage MJ; Carroll CA; Fairman KA
    J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis.
    Kozma CM; Phillips AL; Meletiche DM
    J Manag Care Spec Pharm; 2014 Aug; 20(8):800-7. PubMed ID: 25062073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.
    Munsell M; Frean M; Menzin J; Phillips AL
    BMC Neurol; 2017 Jun; 17(1):106. PubMed ID: 28583104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
    Alvarez E; Nair KV; Tan H; Rathi K; Gabler NB; Maiese EM; Deshpande C; Shao Q
    J Med Econ; 2023; 26(1):494-502. PubMed ID: 36970763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
    Lundy J; Craig BM
    Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
    Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
    J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
    Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K
    J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study.
    Ng HS; Zhu F; Zhao Y; Yao S; Lu X; Ekuma O; Evans C; Fisk JD; Marrie RA; Tremlett H
    Neurology; 2024 Feb; 102(3):e208006. PubMed ID: 38181306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing use of disease modifying drugs for MS in Canada.
    Rotstein DL; Mamdani M; O'Connor PW
    Can J Neurol Sci; 2010 May; 37(3):383-8. PubMed ID: 20481274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.
    Brandes DW; Raimundo K; Agashivala N; Kim E
    J Med Econ; 2013; 16(4):547-51. PubMed ID: 23391123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
    Birnbaum HG; Ivanova JI; Samuels S; Davis M; Cremieux PY; Phillips AL; Meletiche D
    Curr Med Res Opin; 2009 Apr; 25(4):869-77. PubMed ID: 19232041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
    Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
    J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.
    Bruno D; Marc D; Ouarda P; Dominique S; Marc S; Laurène C; Khalil J; Jonathan E; Francis G
    Mult Scler Relat Disord; 2019 Nov; 36():101396. PubMed ID: 31525627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.